2.41
+0.08(+3.43%)
Currency In USD
| Previous Close | 2.33 |
| Open | 2.35 |
| Day High | 2.48 |
| Day Low | 2.35 |
| 52-Week High | 3.67 |
| 52-Week Low | 0.99 |
| Volume | 1.92M |
| Average Volume | 4.13M |
| Market Cap | 232M |
| PE | -1 |
| EPS | -2.4 |
| Moving Average 50 Days | 2.52 |
| Moving Average 200 Days | 1.89 |
| Change | 0.08 |
If you invested $1000 in Cabaletta Bio, Inc. (CABA) since IPO date, it would be worth $241 as of December 19, 2025 at a share price of $2.41. Whereas If you bought $1000 worth of Cabaletta Bio, Inc. (CABA) shares 5 years ago, it would be worth $192.8 as of December 19, 2025 at a share price of $2.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoim
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
GlobeNewswire Inc.
Oct 27, 2025 11:00 AM GMT
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis regi
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-sta